Von Hippel-Lindau Disease (VHL) is a rare genetic disorder characterized by the development of tumors and cysts in various parts of the body. It is estimated to affect approximately 1 in 36,000 individuals worldwide.
VHL is an autosomal dominant condition, meaning that a person only needs to inherit one copy of the mutated gene from either parent to develop the disease. The prevalence of VHL can vary among different populations, but it is considered a relatively rare disorder.
The disease can manifest in multiple organs, including the brain, spinal cord, kidneys, adrenal glands, pancreas, and eyes. Symptoms and complications can vary widely depending on the location and size of the tumors or cysts.
Early diagnosis and regular monitoring are crucial for managing VHL and preventing potential complications. Genetic testing can help identify individuals at risk, allowing for proactive medical interventions.
While VHL is a rare condition, it is important to raise awareness about the disease and support affected individuals and their families in their journey.